Tilray Inc. (TLRY) saw its stock surge 5.12% in after-hours trading, reflecting heightened investor optimism in the cannabis sector.

The rally follows multiple reports indicating U.S. President Donald Trump is poised to sign an executive order rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. This move would lift the crippling IRS Section 280E tax burden, allowing cannabis companies like Tilray to deduct standard business expenses and potentially achieve profitability.

Sector-wide gains were observed as investors bet on the transformative impact of rescheduling, which could also ease research restrictions and improve access to capital for cannabis firms. Tilray, as a key player in the industry, stands to benefit significantly from these regulatory changes.